Clinical Trial Update: REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating REGN7508 for the prevention of cancer-associated thrombosis in adult participants is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer-associated Thrombosis

Drugs mentioned

• REGN7508

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Cancer-Associated Thrombosis (CAT) | Phase 3 | Status: RECRUITING